#VisualAbstract: Use of inhaled corticosteroids is not associated with improved COVID-related mortality in patients with chronic respiratory conditions


2. Among asthma patients, a high-dose, but not low- or medium-dose, of inhaled corticosteroids was associated with an increased risk of COVID-related mortality compared SABAs only. 

Evidence Rating Level: 2 (Good)

Study Rundown: Early reports have described a relatively lower prevalence of COVID-19  than would be expected among patients with chronic respiratory conditions. These early findings have lead to speculations that the use of inhaled corticosteroids (ICS) – a commonly prescribed medication for respiratory disease – may have a protective function against SARS-CoV-2 infection. This observational cohort study sought to evaluate an association between ICS use and COVID-19-related death among patients with chronic obstructive pulmonary disease (COPD) and asthma. Patients on long-acting β agonist plus long-acting muscarinic antagonist (LABA-LAMA) dual therapy experienced fewer complications than those who were prescribed an ICS combination. Similarly, fewer asthma exacerbations were reported among individuals in the short-acting β agonist (SABA)-only group compared to those taking high-dose ICS. These results suggest that regular ICS use among patients with chronic respiratory disease is not associated with beneficial effects for COVID-19-related mortality. This study was limited by the presence of several confounding variables and misclassification, with some patients being incorrectly labelled as using a certain medication. Nonetheless, this study provides important insight into the role of inhaled corticosteroids in COVID-19-related clinical outcomes among a large group of patients in the UK.

Click to read the study in The Lancet Respiratory Medicine

Relevant Reading: Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19

In-depth [prospective cohort]: This observational cohort study followed 148 557 COPD patients and 818 490 asthma patients from March 1, 2020 to May 6, 2020 in England, UK. In the COPD population, 29.2% (n=43 308) of individuals were given a LABA-LAMA prescription and 70.8% (n=105 249) were given an ICS-LABA or ICS-LABA-LAMA prescription four months prior to enrolment. In the asthma population, 13.2% (n=108 441) of patients were given SABA-only, 12.3% (n=101 077) were given high-dose ICS, and the remaining 74.4% (n=608 972) received low-dose or medium-dose ICS. In both cohorts, the median follow-up time was 66 days (IQR 66-66).

For patients with COPD, median age was 71  years (IQR 63-77) for those in the LABA-LAMA combination group and 72 years (IQR 64-78) for those in the ICS combination group. For patients diagnosed with asthma, the median age was 48 years (IQR 35-60) in the SABA-only group, 53 years (40-66) in the low- or medium-dose ICS group, and 55 years (44-67) in the high-dose ICS group. Altogether, 429 COVID-19-related deaths occurred in the COPD cohort, with individuals on ICS combination having an increased risk of COVID-19-related fatality (adjusted Hazard Ratio [HR] 1.39, 95% CI 1.10-1.76). In the asthma population, 529 COVID-19-related deaths occurred. Here, individuals that were prescribed high-dose ICS had an increased risk of COVID-19-related complications (adjusted HR 1.55, 95% CI 1.10-2.18 for high-dose ICS) compared to individuals in the SABA-only group. A similar pattern was noted for the risk of non-COVID-19-related death. In the COPD cohort, the risk was higher among individuals prescribed ICS compared with those prescribed LABA-LAMA (HR 1.23, 95% CI 1.08-1.40). In conclusion, the authors found no evidence of a protective effect of ICS on COVID-19-related mortality among patients with COPD and asthma.

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.


Next Post

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

Get Full Access

Register now to get free full access to over 8000 searchable archived reports, visual abstracts, Classics Series landmark trials, weekly rewinds, and much more.

Welcome Back!

Login to your account below

Create New Account!

Fill the forms below to register

Retrieve your password

Please enter your username or email address to reset your password.